Compare Becton Dickinson and Co (BDX) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Starbucks Corp — how do they compare? Becton Dickinson and Co trades at $155.18 (market cap $41.51B), while Starbucks Corp trades at $106.21 (market cap $121.00B). The key difference: Starbucks Corp is far larger — about 2.9× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | SBUX | |
|---|---|---|
Market Cap | $41.51B | $121.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $107.34 |
52-Week Low | $135.49 | $78.46 |
Enterprise Value | $57.97B | $143.69B |
Dividend Yield | 2.79% | 2.34% |
Volume | — | 7,493,833 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Starbucks (SBUX) trades at $107.34, up 1.25% on the day, with a bullish technical signal from moving averages and near the consensus price target of $108.31. Recent Q2 2026 results showed revenue of $9.53B and EPS beat expectations, while the company focuses on cost-cutting through AI initiatives. The stock exhibits strong support at $107 and faces resistance at $108.
The outlook is cautiously optimistic with analyst consensus leaning buy (47.46%), but high P/E of 81.94 and declining net income margins pose valuation concerns. Key risks include execution of AI cost savings and competitive pressures, while dividend growth and loyalty program strength offer stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
